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ABSTRACT
Osteosarcoma and Ewing Sarcoma are the two most common types of Bone 
Sarcomas, principally localized at the long bones of the extremities and mainly 
affecting adolescents and young adults. Cisplatin is one of the current options in the 
therapeutic arsenal of drugs available to cure these aggressive cancers. Unfortunately, 
chemoresistance against this agent is still a major cause of patient relapse. Thus, a 
better understanding of the molecular pathways by which these drugs induce cancer 
cell death, together with a better delineation of the origins of chemoresistance are 
required to improve the success rate of current treatments. Furthermore, as p53 is 
frequently mutated in Bone Sarcomas, other pathways in these cancers must mediate 
drug-induced cell death. Here, we demonstrate for the first time that TAp73β, a 
p53-family protein, is implicated in Cisplatin-induced apoptosis of Bone Sarcomas’. 
Furthermore, while acquired resistance developed by cancer cells against such 
drugs can have multiple origins, it is now well accepted that epigenetic mechanisms 
involving microRNAs (miRNAs) are one of them. We show that miRNA-193a-5p 
modulates the viability, the clonogenic capacity and the Cisplatin-induced apoptosis 
of the Bone Sarcoma cells through inhibition of TAp73β. Collectively, these results 
shed light on the involvement of miR-193a-5p in Cisplatin chemoresistance of Bone 
Sarcomas’, and they open the road to new therapeutic opportunities provided by 
targeting the miR-193a-5p/TAp73β axis in the context of these malignancies.
INTRODUCTION
While they are relatively uncommon cancers, 
Osteosarcoma and Ewing Sarcoma are the two most 
frequent types of Primary Bone Sarcomas, affecting 
both children and young adults. Resulting from a bone-
remodeling processes’ deregulation, these aggressive 
tumors mainly arise at the long bones of the extremities, 
and are characterized by an ectopic and anarchic osteoid 
neo-formation associated with osteolysis. With an 
incidence of 4 to 5 cases per million and a peak around 18 
years old, Osteosarcoma is by far the most common type 
of these neoplasms [1, 2]. Although no specific genetic 
lesions have been uncovered until now to distinguish 
these tumors, the locus of the tumor suppressor p53 
gene is altered in about 50% of the patients [3, 4]. With 
approximately 225 new cases diagnosed per year in 
the United-States, Ewing Sarcoma is the second most 
common Bone cancer after Osteosarcoma [5]. It displays 
an incidence peak around 15 years of age and a slight 
prevalence in males [6, 7]. In 85% of the cases, Ewing 
Sarcoma is outlined by the chromosomal translocations 
t(11;22)(q24;12), giving rise to the chimeric transcription 
factor EWS-Fli1, whose the oncogenic features are well 
documented [8]. In addition, a mutational hot-spot of p53 
was suggested in Ewing Sarcoma, as the same missense 
mutation at codon 176 was found in several samples from 
primary tumors [9]. 
Presently, the standard of care for young patients 
suffering from Bone Sarcomas is based on a multimodal 
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therapy including neo-adjuvant chemotherapy and surgical 
resection, together with local radiotherapy and adjuvant 
chemotherapy [5, 10]. Such treatments have markedly 
improved the outcomes of the patients worldwide, since 
the 5-year survival rates after treatment approach 60-70% 
for the localized forms. Unfortunately, chemoresistance, 
tumor burden and pulmonary metastases at the time of 
diagnosis all confer a very poor prognosis, and survival 
rates drop to around 30% in these cases [11]. The 
unsatisfactory outcomes for such patients and the toxicity 
-based limitations of current chemotherapeutic agents 
both underscore the urgency of finding novel therapeutic 
strategies. In this context, there is a real need to better 
understand the relevant drug-induced cell death processes 
and chemoresistance-related mechanisms.
The P73 gene is a member of the P53-related 
transcription factor family. It plays a crucial role during 
embryonic development and tumor progression, through 
mechanisms involving control of the genome stability and 
chemosensitivity [12-17]. Although P53 and P73 display 
a common architecture, with several highly homologous 
domains, different promoters and alternative splicings 
contribute to the generation of a considerable number 
of distinct P73 isoforms. Longer isoforms bearing the 
trans-activating N-terminal domains are called the TA 
isoforms and mimic the tumor-suppressor function of 
p53 through their ability to trans-activate apoptotic 
transcriptional target-genes such as p21, Noxa or PUMA 
[18]. On the contrary, the ΔNp73 isoforms, lacking the TA 
domain, have a rather dominant-negative function [19]. 
Although P53 is mutated or inactivated in about 50% of 
the human cancers, it is rarely the case for P73, making 
it a potent drug-induced-cell-death mediator [20, 21]. It 
is thus noteworthy that the expression of P73 modulates 
chemosensitivity of several cancer types. Nonetheless, this 
feature remains to be investigated in the Bone Sarcomas’ 
context [22]. 
It has already been established that miRNA-193a-5p 
is implicated in P73 regulation [23]. miRNAs are small 
non-coding RNAs involved in the post-transcriptional 
regulation of the gene expression. As they act as key 
regulators of multiple target-genes, they are able to fine-
tune various physiological processes and are aberrantly 
deregulated in several diseases including cancers [24-26]. 
These features together with their substantial stability 
could therefore make them potent bio-markers, novel 
targets or powerful drugs [27]. We have already described 
that the TAp73β isoform is a mediator of Cisplatin-induced 
apoptosis in a head and neck squamous cell carcinoma 
model [23]. Additionally, we also demonstrated that 
through modulating the expression of TAp73β, the miR-
193a-5p was a key component of an endogenous Cisplatin-
chemoresistance mechanism. In this study, we sought to 
determine if the TAp73β/miR-193a-5p axis could also be 
implicated in the Cisplatin-resistance of Bone Sarcomas. 
We observed that inhibiting TAp73β reduces the caspase 
activity and increases both the clonogenic features and the 
cell’s Cisplatin-resistance. Moreover, blocking the Bone 
Sarcoma cells’ endogenous miR-193a-5p expression 
reverses such effects, leading to Cisplatin-sensitization. 
Such results shed light on the role of the miR-193a-5p in 
the Bone Sarcomas’ Cisplatin-chemoresistance and open 
the road to new therapeutic opportunities provided by its 
targeting in an attempt to improve the outcome of these 
pediatric cancers. 
RESULTS
Human Bone Sarcoma cells express TAp73β and 
the miR-193a-5p and are Cisplatin- sensitive
To directly assess the relevance of studying the 
TAp73β/miR-193a-5p axis in the drugs-resistance 
mechanisms of Bone Sarcomas, we first evaluated the 
expression of TAp73β at mRNA level and the miR-193a-
5p’s expression in seven Osteosarcoma cell lines and in 
seven Ewing Sarcoma cell lines (Figure 1a, 1b). As the 
JHU-029 head and neck squamous carcinoma cells were 
previously used as a model to study the p63/miR193a-
5p/p73 axis, they were included in our screening and 
serves as a control [23]. All the cell lines express TAp73β 
except the CAL-72 one, potentially because it is the only 
Osteosarcoma cell line of our panel displaying a wild-type 
and functional p53 status (Figure 1a, Supp. Figure 1). In 
addition, the 143B cell line displays the highest expression 
of this apoptotic factor. It is indeed about 50% more 
elevated than in the JHU-029 carcinoma cells previously 
presented as over-expressing it [23]. The SaOS2, SJSA-
1, HOS, EW24 and SKES-1 cells display an intermediate 
expression level, whereas this transcription factor is 
barely detectable in the other cell lines. The miR-193a-5p 
is expressed in all the cell lines tested, but significantly 
more in the Osteosarcoma cells compared to the Ewing 
Sarcoma ones (Figure 1b). These results strongly suggest 
the implication of the miR-193a-5p in Osteosarcoma-
specific cellular processes but nevertheless fully justify 
pursuing this work in both Bone Cancer types in order 
to assess the impact of such discrepancy in the drug-
resistances’ context. The same Bone Sarcoma cells’ panel 
was treated with Cisplatin to assess its effects on the cell 
viability (Figure 1c, 1d, 1e). A concentration-dependent 
inhibition of cell viability was observed in all the cell lines 
studied with important variability of the GI50. The Ewing 
Sarcoma cells A673, EW24 and IOR/BRZ are the more 
sensitive ones as they exhibited GI50 between 1.472 and 
2.296 µM (Figure 1d, 1e). With GI50 comprise between 
4.067 and 11.95 µM, the SJSA-1, CAL-72, 143B, HOS, 
U2OS, TC32, RDES, TC71 and SKES-1 cells display an 
intermediate sensitivity. In contrast, the MG63 and SaOS2 
cell lines are twenty to forty times less sensitive compared 
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Figure 1: Human Bone Sarcoma cells express TAp73β and the miR-193a-5p and are Cisplatin- sensitive. a. Expression 
of TAp73β and b. miR-193a-5p were evaluated by qRT-PCR in seven human Osteosarcoma (black patterns) and seven Ewing Sarcoma 
(grey patterns) cell lines and compared with the ones of the human head and neck squamous carcinoma cells JHU-029 (white pattern). 
Glyceraldehyde-3-phosphate dehydrogenase, β2-microglobulin and RNU6B were used as housekeeping genes. Error bars show standard 
deviation for n = 3 measurements from representative experiments. c. Seven human Osteosarcoma cell lines (143B, CAL-72, HOS, SaOS2, 
SJSA-1, MG63 and U2OS) and d. seven Ewing Sarcoma cell lines (A673, EW24, IOR/BRZ, TC32, TC71, SKES-1 and RDES) were 
cultured for 48 h in the presence of Cisplatin at the indicated concentrations and cell viability was determined by WST-1 assay. The head 
and neck squamous cell carcinoma cell line JHU-029 was used as a reference cell line. The viability of the non-treated control of each 
cell line was assigned as 100%. e. GI50 for Cisplatin in tumor cell lines. f. Correlation between the Cisplatin GI50 and the miR-193a-5p 
expression in the human Bone Sarcoma cell lines, assessed by WST-1 assay and by qRT-PCR and tested by the Pearson product-moment 
correlation test. g. GI50 for Cisplatin in Osteosarcoma (black patterns) and Ewing Sarcoma cell lines (grey patterns). h. miR-193a-5p’s 
expression in Osteosarcoma (black patterns) and Ewing Sarcoma cell lines (grey patterns). An unpaired Student’s t-test was used to compare 
the differences between the mean values of the Cisplatin-GI50 and the miR-193a-5p’s expression in the Osteosarcoma and in the Ewing 
Sarcoma cell lines.
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with the first ones, with a GI50 of 24.85 µM and around 
45.57 µM respectively. Interestingly, those two cell lines 
are the ones displaying the highest miR-193a-5p levels 
(Figure 1b). A statistically significant correlation was 
found between the GI50 and the miR-193a-5p expression 
level in all the cell lines, reinforcing the hypothesis 
of the miR-193a-5p’s involvement in the Cisplatin-
chemoresistance in such model (Figure 1f). In addition, 
a non-significant higher global average GI50 is observed 
in the Osteosarcoma compared with the Ewing Sarcoma 
cells (Figure 1g). Interestingly, a significant higher global 
expression of the miR was also found in the Osteosarcoma 
cell lines compared with the Ewing Sarcoma ones (Figure 
1h), arguing again in favor of its presumed implication in 
the Cisplatin-chemoresistance. Following investigations 
were thus based on the hypothesis that a high miR-
193a-5p expression could induce a high Cisplatin-
chemoresistance due to the miRNA-inhibitor’s effects on 
TAp73β’s expression. The cell lines were thus chosen for 
further analysis based on their TAp73β and miR-193a-5p 
expression levels.
Cisplatin modulates the expression level of the 
miR-193a-5p, TAp73β and its target-genes in 
Bone Sarcoma cells
To better understand to what extent the miR-193a-
5p/TAp73β axis is involved in the Cisplatin-response of 
the Bone Sarcoma cells, the RDES Ewing Sarcoma cell 
line and the SJSA-1 Osteosarcoma one were treated or 
not with 3 µM Cisplatin during twenty-four hours and the 
expression levels of the miR-193a-5p, TAp73β and two of 
its target-genes, p21 and MDM2 were assessed by qRT-
PCR (Figure 2a, 2b, 2c, 2d and Supp. Figure 2a, 2b, 2c, 
2d). In the RDES cells, we can notice that the Cisplatin 
induces a down-regulation of the miR-193a-5p from 
about 82% compared with the non-treated control cells. 
As expected, the expression levels of TAp73β and two of 
its direct targets are strongly increased in these conditions. 
Similar results were observed in the SJSA-1 cells except 
for MDM2 expression (Supp. Figure 2a, 2b, 2c, 2d). Those 
two cell lines were picked because of their relatively low 
TAp73β expression level allowing and easier activation 
observation. These results highlight the inhibitory effect 
of the Cisplatin on the expression of the miR-193a-5p, but 
the exact underlying mechanism needs to be investigated.
TAp73β-mediated Cisplatin sensitivity of human 
Bone Sarcomas
In order to better delineate to what extent TAp73β 
is implicated in the Cisplatin-response of Bone Sarcoma 
cells, TAp73 was down-regulated with siRNAs in 
the RDES Ewing Sarcoma cell line used in Figure 2 
(with a low TAp73β expression level) and in the 143B 
Osteosarcoma one because they express the highest 
TAp73β level of all the cell lines tested (Figure 3a and 
Supp. Figure 3a). According to the tumor suppressive 
functions of TAp73 [28], the consequent 50% reduction 
of TAp73β’s expression obtained in the RDES cell line 
(Figure 3a) leads to a significant diminution of its caspase 
3/7 activity, supporting the implication of the TAp73β 
isoform in the apoptotic processes in these cells (Figure 
3b). Moreover, these results are linked to the improved 
clonogenic capabilities observed in these conditions, as 
the TAp73si-cells were able to form about 2.5 times more 
clones in 2D than the GFPsi ones (Figure 3c). In addition, 
the implication of TAp73 in the Cisplatin-sensitivity of the 
RDES cells was highlighted by the fact that a reduced-
TAp73 expression in those cells contributes to reduce their 
sensitivity to Cisplatin in a viability assay (Figure 3d). The 
same effects were confirmed in the 143B Osteosarcoma 
cells after TAp73 inhibition, even if this cell line displays 
the highest TAp73β expression level compared with the 
other cell lines (Supp. Figure 3a, 3b, 3c, 3d and Figure 1a). 
Together, these data support the implication of TAp73 in 
Figure 2: Cisplatin modulates the expression level of the miR-193a-5p, TAp73β and its target-genes in Bone Sarcoma 
cells. Expression of miR-193a-5p a., TAp73β b., p21 c. and MDM2 d. were evaluated by qRT-PCR in the RDES Ewing Sarcoma cell line 
after treating the cells or not during twenty-four hours with 3 µM Cisplatin. RNU6B, Glyceraldehyde-3-phosphate dehydrogenase and 
β2-microglobulin were used as housekeeping genes. Error bars show the standard deviation for n = 3 measurements from representative 
experiments. 
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both the apoptotic and the clonogenic processes, revealing 
that this gene is related to the Cisplatin-sensitivity in the 
Bone Sarcoma cells. These results raise the question 
of the implication of the miR-193a-5p in the Cisplatin-
chemoresistance though its ability to regulate TAp73β.
The TAp73β’s targeting miR-193a-5p is 
implicated in the Cisplatin chemoresistance of 
human Bone Sarcomas
To assess the impact of the miR-193a-5p in the 
Cisplatin-resistance, its overexpression was performed 
in the RDES Ewing Sarcoma cell line and in the SJSA-
1 Osteosarcoma one. These two cell lines display a non-
functional p53 protein, weakly express both TAp73β 
and the miR-193a-5p and exhibit the same intermediate 
Cisplatin sensitivity as shown by their equivalent GI50 
(Figure 1 and Supp. Figure 1). Such features raise 
the opportunity to easily increase the miR-193a-5p’s 
expression level by transient transfections of pre-miRNAs 
and make them interesting models in the context of 
our study. The pre-miR-193a-5p was thus transiently 
transfected and the cells were treated forty-eight hours 
later with Cisplatin (Figure 4 and Supp. Figure 4). The 
transfection’s efficiency was validated by qRT-PCR in both 
cell lines (Figure 4a and Supp. Figure 4a). The consequent 
expected down-regulation of TAp73β, p21 and MDM2 
was also verified at transcriptional level (Figure 4b, 4c, 
4d and Supp. Figure 4b, 4c, 4d). In absence of Cisplatin, 
increasing the miR-193a-5p’s expression induces a slight 
reduction in the caspase 3/7 activity (Figure 4e and Supp. 
Figure 4e), corroborating the previous results obtained 
after reducing the expression of TAp73 (Figure 3b and 
Supp. Figure 3b). The same effect is observed after a 3 
µM Cisplatin-treatment. Increasing the miR-193a-5p’s 
expression significantly reduces the caspase 3/7 activity by 
14.13 and by 13.23% in the RDES and in the SJSA-1 cells 
Figure 3: TAp73β-mediated sensitivity of human Bone Sarcomas: regulation of apoptosis and clonogenicity. a. Expression 
of TAp73β was evaluated by qRT-PCR in the RDES Ewing Sarcoma cell line, after infecting the cells with viral-supernatant of GFPsi 
-or TAp73si-transduced HEK293FT cells. Glyceraldehyde-3-phosphate dehydrogenase and β2-microglobulin were used as housekeeping 
genes. b. The basal apoptosis level was then evaluated by dosage of the caspase 3/7 activity in protein extracts from the same cells and 
in the same conditions as in (a). Error bars show the standard deviation for n = 3 measurements from representative experiments. c. The 
basal clonogenic capabilities of the cells were evaluated in the same cells and in the same conditions as in (a). One thousand cells were 
seeded in 6-wells plates and incubated until the possibility of macroscopic clones counting. The cells were then fixed in glutaraldehyde and 
stained with Crystal Violet. Error bars show the standard deviation for n = 3 measurements from representative experiments. Representative 
pictures of the wells in each condition were chosen. An unpaired Student’s t-test was used to compare the different conditions in the caspase 
3/7 activity assays and in the clonogenic assays. d. The same cells in the same conditions as in (a) were cultured for 48 h in the presence of 
Cisplatin at the indicated concentrations and cell viability was determined by WST-1 assay. The viability of the non-treated control of each 
cell line was assigned as 100%. A two-way ANOVA test was used to compare the different conditions in the viability assays. 
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respectively. Inducing the expression of the miR-193a-5p 
also reduces the Poly-(ADP-ribose) polymerase (PARP) 
cleavage induced by the Cisplatin (Figure 4f and Supp. 
Figure 4f) and improves the cell viability after only two 
hours of Cisplatin treatment in both cell lines (Figure 4g 
and Supp. Figure 4g). Taking together, these results argue 
for the anti-apoptotic role of the miR-193a-5p, through its 
TAp73β’s targeting capabilities and strongly support its 
implication in the Cisplatin-chemoresistance in this model.
The TAp73β-mediated Cisplatin-induced cell 
death is countered by miR-193a-5p in human 
Bone Sarcoma cells
To address the ability of miR-193a-5p to modulate 
the Cisplatin sensitivity of Bone Sarcoma cells through 
targeting TAp73β, a modulation of the expression level of 
both partners was performed. The MG63 cells display one 
of the highest basal Cisplatin chemoresistance, probably 
due to their elevated miR-193a-5p’s expression level and 
their weak basal TAp73b’s expression level compared 
with all the Bone Sarcoma cell lines previously screened 
(Figure 1). Regarding those features, this cell line appears 
as the best model to follow this strategy. To assess the 
implication of TAp73β in the Cisplatin-chemoresistance 
in this cell line, the cells were first transiently transfected 
with a TAp73β coding vector only. The efficiency of the 
transfection was validated by qRT-PCR, as the expression 
of TAp73β was about five thousand times more elevated 
in the TAp73β-transfected cells than in the control ones 
(Figure 5a left panel). These results were also confirmed 
at protein level, however in a lower extent (Figure 5a 
right panel). Such increase has a functional effect on the 
cell viability, increasing the cell sensitivity in response 
to a four-days Cisplatin treatment at each concentration 
tested (Figure 5b). Moreover, increasing the expression 
of TAp73β markedly improve the Cisplatin-induced 
caspase 3/7 activity (Figure 5c). Nonetheless, increasing 
the expression of the TAp73β-targeting miR-193a-5p 
significantly decreases the caspase 3/7 activities by 
Figure 4: The TAp73β’s targeting miR-193a-5p is implicated in the Cisplatin chemoresistance of human Bone 
Sarcomas. a. miR-193a-5p expression was assessed by qRT-PCR in the RDES Ewing Sarcoma cell line forty-eight hours after either the 
pre-miR control or the pre-miR-193a-5p mimic’s transfection. The expression of TAp73β b., p21 c. and MDM2 d. were assessed by qRT-
PCR in the same conditions as described in (a). RNU6B, Glyceraldehyde-3-phosphate dehydrogenase and β2-microglobulin were used as 
housekeeping genes for qRT-PCR and the error bars show the standard deviation for n = 3 measurements from representative experiments. 
e. RDES Ewing Sarcoma cell line was transiently transfected in the same conditions as in (a) and was treated forty-eight hours later with 
3 µM Cisplatin or the same amount of NaCl 0.9% for additional forty-eight hours. The apoptosis was then evaluated by dosage of the 
caspase 3/7 activity in protein extracts. Error bars show the standard deviation for n = 3 measurements from representative experiments. 
A two-tailed paired Student’s t-test was used to compare the different conditions in the caspase 3/7 activity assays. f. Protein’s extracts 
from RDES Ewing Sarcoma cell line in same conditions as in (a) were subjected to Immunoblotting with anti-cleaved-PARP antibodies. 
Glyceraldehyde-3-phosphate dehydrogenase was used as loading control. g. RDES Ewing Sarcoma cell line was transiently transfected 
with either pre-miR control or pre-miR-193a-5p mimics and was cultured forty-eight hours later in the presence of Cisplatin at the indicated 
concentrations for two hours. The cell viability was determined by WST-1 assay and compared with control. The viability of the non-treated 
control was assigned as 100%. A two-way ANOVA test was used to compare the different conditions in the viability assays. Data refer to 
three different experiments and western blot images are representative of these. Black lines show where the original gel was cropped to 
obtain the final image
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22.5%. Finally, as predicted by those data, increasing the 
expression of the miR-193a-5p counteracts the Cisplatin-
chemo-sensitizing effects of TAp73β on the cell viability 
(Figure 5d).
Inhibiting the miR-193a-5p increases the 
expression of TAp73β and restores the Cisplatin-
sensitivity of human Bone Sarcoma cells
As TAp73β is a target of the miR-193a-5p, we 
hypothesized that decreasing the endogenous expression 
level of this miR may have the same consequences on 
the Cisplatin-sensitivity than over-expressing TAp73β. 
We then tested our sensitizing strategy on the partially 
Cisplatin-resistant cell line MG63, moreover expressing 
high level of miR-193a-5p. The MG63 cells were thus 
transfected with a control anti-miR or the anti-miR-
193a-5p and the efficiency of transfection was validated 
by qRT-PCR (Figure 6a). As expected, the expression of 
TAp73β and two of its target-genes (p21 and MDM2) 
was increased (Figure 6b, 6c, 6d, 6e). The functional 
consequence of such modulation was assessed on the 
caspase 3/7 activities and on the clonogenic capabilities 
of those cells (Figure 6f, 6g). Without Cisplatin-treatment, 
inhibiting the expression of the miR only leads to a slight 
non significant increase of the caspase activity (Figure 6f) 
but significantly decreases the cell colony-forming ability 
(Figure 6g). In addition, inhibiting the expression of the 
miR-193a-5p potentiates the effects of the Cisplatin on 
the cell viability, significantly sensitizing the cells to this 
agent (Figure 6h). In addition, the use of the anti-miR-
193a-5p also displays a chemo-sensitizer’s effect both on 
the 143B Osteosarcoma and the RDES Ewing Sarcoma 
cells, in which the expression of TAp73β was artificially 
reduced (Supp. Figure 5a and b). Taken together, these 
Figure 5: The TAp73β-mediated Cisplatin induced cell death is opposed by the miR-193a-5p in human Bone Sarcoma 
cells. a. The TAp73β’s expression was assessed in the MG63 Osteosarcoma cell line both at mRNA level by qRT-qPCR (left panel) and 
at protein level by Western Blotting (right panel) forty-eight hours after the cell’s transient transfection with the empty vector pcDNA3 or 
the TAp73β one. Glyceraldehyde-3-phosphate dehydrogenase and β2-microglobulin were used as housekeeping genes for qRT-PCR. Actin 
was used as a loading control for Immunoblotting. b. MG63 Osteosarcoma cell line was transiently transfected with either the empty vector 
pcDNA3 or the TAp73β one and was cultured forty-eight hours later in the presence of Cisplatin at the indicated concentrations for four 
days. The cell viability was determined by WST-1 assay and compared with control. The viability of the non-treated control was assigned 
as 100%. Error bars show the standard deviation for n = 2 measurements from representative experiments. An unpaired Student’s t-test 
was used to compare the different conditions in the viability assays. c. MG63 cells were transiently transfected with either the pre-miR 
control or the pre-miR-193a-5p as the same time as pcDNA3 empty vector or the TAp73β containing-one. The cells were then cultured 
forty-eight hours later in the presence of 3 µM Cisplatin for additional forty-eight hours. The apoptosis was then evaluated by dosage of the 
caspase 3/7 activity in protein extracts. Error bars show the standard deviation for n = 3 measurements from representative experiments. 
A two-tailed paired Student’s t-test was used to compare the different conditions in the caspase 3/7 activity assays. d. MG63 cells were 
transiently transfected with either the pre-miR control or the pre-miR-193a-5p as the same time as pcDNA3 empty vector or the TAp73β 
containing-one. The cells were then cultured forty-eight hours later in the presence of 3 µM Cisplatin at the indicated concentrations for 
additional forty-eight hours. The cell viability was determined by WST-1 assay and compared with control. The viability of the non-treated 
control was assigned as 100%. 
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results bring the proof of concept that artificially inhibiting 
the miR-193a-5p expression could be a useful strategy 
to potentiate the Bone Sarcoma cell’s sensitivity to the 
Cisplatin. 
DISCUSSION
The chemoresistance developed by the tumor’s cells 
is one of the main causes of the cancer-therapies’ failure, 
especially in Bone Sarcomas which are very aggressive and 
in which only few therapeutic options are available. The 
origins of the acquired drug-resistance can be multiple, but 
a progressive loss of expression of tumor-suppressor genes 
along the treatment-course often occurs in cancer cells. 
As these genes normally sense the genotoxic stress or 
mediate the drug-induced apoptotic response, such cancer 
cells can overcome the chemotherapeutic agents’ effects. 
Beyond the mutational processes that can affect such 
tumor-suppressor’s expression or activity, their silencing 
by the miRNAs is an epigenetic mechanism that has been 
well accepted to deregulate the drug-resistance-related 
genes. Unfortunately, only a few studies are available in 
Figure 6: Inhibiting the miR-193a-5p increases the expression of TAp73β and restores the Cisplatin-sensitivity of 
human Bone Sarcoma cells. a. miR-193a-5p’s expression was assessed by qRT-PCR in the MG63 Osteosarcoma cell line forty-eight 
hours after either the anti-miR control or the anti-miR-193a-5p’s transfection. TAp73β’S expression was assessed by qRT-PCR b. and by 
Western Blotting c. in the same conditions as described in (a). Glyceraldehyde-3-phosphate dehydrogenase and β2-microglobulin were 
used as housekeeping genes for qRT-PCR and actin serves as Immunoblotting’s loading control. The expression of p21 d. and MDM2 e. 
were assessed by qRT-PCR in the same conditions as described in (a). β2-microglobulin was used as housekeeping genes for qRT-PCR. For 
the qRT-PCR experiments, error bars show the standard deviation for n = 3 measurements from representative experiments. f. The basal 
apoptosis level was then evaluated by dosage of the caspase 3/7 activity in protein extracts from the same cells and in the same conditions as 
in (a). Error bars show the standard deviation for n = 3 measurements from representative experiments. g. The basal clonogenic capabilities 
of the cells were evaluated in the same cells and in the same conditions as in (a). One thousand cells were seeded in 6-wells plates and 
incubated until the possibility of macroscopic clones counting. The cells were then fixed in glutaraldehyde and stained with Crystal Violet. 
Error bars show the standard deviation for n = 3 measurements from representative experiments. Representative pictures of the wells in 
each condition were chosen. A two-tailed paired Student’s t-test was used to compare the different conditions in the caspase 3/7 activity 
assays and in the clonogenic assays. h. MG63 Osteosarcoma cell line was transiently transfected with either the anti-miR control or the 
anti-miR-193a-5p and was cultured forty-eight hours later in the presence of Cisplatin at the indicated concentrations for two hours. The 
cell viability was determined by WST-1 assay and compared with control. The viability of the non-treated control was assigned as 100%. 
A two-way ANOVA test was used to compare the different conditions in the viability assays. 
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the Bone Sarcoma’s context and the precise functions of 
these molecules still need to be deciphered. For instance, 
the miR-34c was reported to be decreased in Cisplatin-
poor responders’ Osteosarcoma patients compared to good 
ones51.
Here, we report that the p53-related tumor-
suppressor gene TAp73β is implicated in the Cisplatin-
induced apoptosis of Bone Sarcomas and that the 
miRNA-193a-5p, through its TAp73β’s targeting ability, 
consequently modulates the Cisplatin-sensitivity of 
these cancers. Interestingly, we have highlighted that 
this mechanism occurs both in Osteosarcoma and Ewing 
Sarcoma, even if the global expression levels of TAp73β 
and the miRNA-193a-5p are lower in Ewing Sarcoma 
(Figure 1a, 1b). The difference in the global expression 
level of TAp73β between these two models might be 
explained by the osteoblastic-origin of Osteosarcoma and 
by the requirement of p73 during the vitamin D-mediated 
osteoblastic differentiation [29]. In addition, this difference 
could also be supported by the fact that human bone 
marrow mesenchymal stem cells, which are the cells of 
origin of Ewing Sarcoma, display a silenced-expression of 
the p73 gene through the hypermethylation of its promoter 
[30]. Furthermore, according to both its p53-related role 
and pro-apoptotic functions, the expression of TAp73 
is often higher in a p53-functionnally deficient cellular-
background [31]. This is in agreement with the wild-
type p53 status of the CAL-72 Osteosarcoma cell line, 
in which no TAp73β expression was detectable (Figure 
1a and Supp. Figure 1). In addition, even if the miRNA-
193a-5p is poorly documented in the Bone context, the 
expression of this miR appears to decrease during the 
osteogenic differentiation of human adipose-derived stem 
cells [32]. However, the miR-193a-3p was reported to be 
five times more elevated in the MG63 Osteosarcoma cell 
line than in the HOB osteoblasts, letting presuming here 
of its oncogenic role [33].
Additionally, this study reports for the first time the 
inhibitory effect of the Cisplatin on the miR-193a-5p’s 
expression of Bone Sarcomas. As a consequence, the 
expression of the pro-apoptotic factor TAp73β and two 
of its target-genes, p21 and MDM2 are increased (Figure 
2 and Supp. Fig.2). Our results are in accordance with a 
previous work, demonstrating that increasing TAp73β’s 
expression leads to a rapid and robust up-regulation of 
p21 in the SaOS2 Osteosarcoma cell line [34]. Through 
overexpression and knockdown experiments, we found 
that TAp73β is implicated in the regulation of both the 
caspase 3/7 activity and the clonogenic capabilities of 
the Bone Sarcoma cells. Thus, such involvement in 
these cellular processes functionally confers to TAp73β 
a mediator role in the Cisplatin-induced apoptosis of the 
Bone Sarcomas. These results corroborate recent studies, 
which have also demonstrated the role of p73 in the 
Cisplatin-related apoptosis in several models [35, 36].
Regarding its p53-redundant-functions, the 
epigenetic regulation of TAp73β through miRNAs has 
already been described and interestingly, even if in silico 
analysis predicts that the miRs -125b, -486-3p and -34a 
could potentially target TAp73 [37], only the miR-193a-
5p was validated as a direct bona-fide TAp73β’s repressor 
[23]. Through modulating the miR-193a-5p’s expression 
level, we highlighted its implication in the Cisplatin-
chemoresistance of the Bone Sarcoma cells, as previously 
shown in a head and neck squamous cell carcinoma model 
[23]. In contradiction with our results (Figure 4e, 5c, 6f 
and Supp. Figure 4e), it was interestingly previously 
reported that the miR-193 is an inducer of the caspase-3 
activity, arguing here for its tumor-suppressive functions 
[38]. In addition, beyond the fact that the miR-193a-
5p can probably inhibit multiple target-genes, it seems 
clear that its dual role in the apoptotic-processes’ control 
could be partially explained by its p73-targeting features. 
Obviously, the different functions of the isoforms of p73 
are not yet fully elucidated and are undoubtedly modulated 
by the interactions of p73 itself with the other members of 
the p53 family, especially p63. In return, this gene-family 
also regulates the expression of this miRNA, as it was 
reported that the oncogenic transcription factor ΔNp63α 
is an inducer of the miR-193a-5p’s expression, thus 
contributing to the Cisplatin-chemoresistance [23]. These 
data could explain a previous study reporting that a stable 
p73 knock-down in breast cancer cell lines induce a higher 
Cisplatin chemoresistance in the cells which express 
ΔNp63 compared with these which do not [36]. 
In summary, we present here evidence for an original 
epigenetic regulatory mechanism placing the TAp73β/
miRNA-193a-5p axis as a major pathway contributing 
to the Cisplatin-sensitivity of the Bone Sarcomas. From 
a therapeutic standpoint, our study highlights the proof-
of-concept that inhibiting the miR-193a-5p expression 
consequently sensitizes the Bone Sarcoma cells to 
the Cisplatin. Finally, this work sustains the relevant 
feasibility of using miRNAs-inhibitors in association with 
standard Cisplatin-treatment to improve the response of 
the young patients treated with this drug. 
MATERIALS AND METHODS
Tumor cell lines and therapeutic agents
Seven human Ewing Sarcoma cell lines were used: 
the A673 TC32, SKES-1 and RDES cell lines, which were 
kindly provided by Dr. S. Burchill (Children’s Hospital, 
Leeds, United Kingdom), the EW24 and TC71 cell lines, 
which were a gift from Dr. O. Delattre (Institut National de 
la Santé et de la Recherche Médicale U830, Paris, France) 
and the IOR/BRZ one. Seven Osteosarcoma cell lines 
were studied: 143B, CAL-72, MNNG/HOS (thereafter 
called HOS), SaOS2, SJSA-1, MG63 and U2OS.All these 
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cells provide from the American Tissue Cell Collection 
(ATCC). The JHU-029 cells were a generous gift of 
David Sidransky, MD (Johns Hopkins University, USA) 
and are used as positive control because of their use in 
the previous study of Ory et al. [23]. HEK 293FT cells 
(Invitrogen, Life Technologies, Carlsbad, CA, USA) are 
used to produce lentiviral particles. See supplementary 
methods for detailed cell culture conditions. The Cisplatin 
powder was provided by Sigma and solubilized in 0.9% 
NaCl solution and stored at -20oC.
Lentiviral and retroviral production
P73-shRNA lentiviral particles were produced by 
transfection of required viral plasmids (4 μg of each: 
RSV-RRE, RGR, VSV-G and 4 μg of TAp73-shRNA; 
TAp73si; or 4μg of GFP-shRNA; GFPsi) following the 
manufacturer’s protocol (CalPhos Transfection Kit; 
Clontech) in HEK 293 FT cell line. The 143B, and the 
RDES cells were infected with HEK 293T supernatants 
(with GFPsi as a control or TAp73si) and selected by 
antibiotic resistance (puromycin, 1μg/mL for the 143B 
cells or 0.5 µg/mL for the RDES ones) for several weeks. 
P73-shRNA targeted sequence is available upon request. 
Transient transfection of pre-miRTM and anti-
miRTM
All the pre-miRTM and anti-miRTM were obtained 
from Ambion and transfected at a final concentration 
of 30 nM using the siPORTNeoFX Transfection Agent 
(Ambion) according tothe manufacturer’s protocol. 
Transient transfection of TAp73β
The TAp73β sequence was inserted in pcDNA3 
vector (Invitrogen). 2μg of DNA were transfected 
using FuGENE® HD Transfection Reagent (Promega) 
according to the manufacturer’s protocol. These assays 
were all performed as described [23].
Cell viability assay and GI50 calculation
Bone Sarcoma cell lines were plated in 96-wells 
plates in the appropriate medium with 10% FBS and 
treated with Cisplatin at indicated concentration during 
48 hours and cell growth was measured using the WST-
1 assay (Roche, Mannheim, Germany). At the end of 
the treatment time, the culture medium is removed and 
replaced by the WST-1 reagent diluted in fresh medium 
in a 1:10 proportion. The absorbance at 470 nm was 
measured on a 96-multiwell microplate reader (Victor² 
1420; PerkinElmer Inc.) and normalized to the average 
reading of wells containing medium only. The GI50 were 
calculated thanks to the GraphPad Prism 6 software. 
2D clonogenic assay
Bone Sarcoma cells were seeded at a density of 
1000 cells per well in 6-wells plate and treated with 3 
µM of Cisplatin or the corresponding amount of NaCl 
0.9% for 48 hours. Culture medium was then replaced 
by fresh one and the cells were cultured for additional 6 
days. The colonies were then washed in PBS, fixed with 
glutaraldehyde 10% and stained with Crystal Violet (1% 
in water). Pictures were taken and five areas/well were 
arbitrary chosen to represent the entire surface of each 
well. The stained surfaces/total surfaces of each area/well 
were calculated thanks to the ImageJ software. 
Apoptotic-cell death assessment
The caspase 3/7 activity was assessed thanks to 
the apo-ONE® Homogeneous caspase-3/7 Assay kit 
(Promega, Madison, USA) according to the manufacturer’s 
instructions. 
Total RNA extraction and quantitative reverse 
transcription-PCR
Total RNA was extracted from cultured-cells using 
the QIAzol Lysis Reagent (QIAGEN) and the miRNeasy 
Mini Kit (QIAGEN) according to the manufacturer’s 
instructions. Total RNA was reversed transcribed using the 
ThermoScript RT-PCR System (Life Technologies). Real-
time monitoring of PCR amplification was performed on 
CFX96 real-time PCR detector system (Bio-Rad, Marnes 
la Coquette, France) with SYBR PCR Master Mix buffer 
(Bio-Rad). Target gene expression was normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
and β-2 microglobulin (B2M) levels in respective samples 
as an internal standard, and the comparative cycle 
threshold (Ct) method was used to calculate the relative 
amplification of target messenger RNAs. The primers 
sequences are described in the Supp. Table 2. 
Quantitative reverse transcription-PCR for 
miRNAs
A specific RT was performed for each miRNA 
from 100 ng of total RNA, using specific stemloop RT 
primers (50 nM) and the MultiScribe Reverse transcriptase 
(Applied Biosystems). The RT conditions were as follows: 
30 minutes at 16oC followed by 30 seconds at 20oC, 30 
seconds at 42oC, 1 second at 50oC for 60 cycles, and 
finally 5 minutes at 85oC. The expression of each gene 
was normalized to the one of the small nuclear U6B RNA 
as a reference. The miRNA’s RT-qPCR-primers’ sequences 
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are detailed in Supp. Table 3 and 4. 
Western blotting analysis
Samples containing equal amounts of protein 
(depending on the antibody, 15-80 mg) from lysates 
of cultured Bone Sarcoma cell lines underwent 
electrophoresis on SDS-PAGE and were transferred 
to polyvinylidene difluoride (PVDF) membranes. The 
membranes were blocked in 3% BSA-PBS-0.05% 
Tween at room temperature for 1 hour and blots were 
probed overnight at 4oC with the primary antibodies. The 
features of the latter are summarized in the Supp. Table 
5. Membranes were then saturated 1 hour with 5% milk-
PBS-0.05% Tween (Régilait) and finally incubated for 
1 hour with secondary antibodies at room temperature 
(Supp. Table 5). Specific proteins were detected using 
SuperSignal® West Dura Extended Duration Substrate 
(ThermoScientific, Rockford, USA) and a G-Box 
(Syngene, Cambridge, UK) after washing. Pictures were 
analysed thanks to the ImageJ software.
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